Business Description
Voyager Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US92915B1061
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 7.9 | |||||
Equity-to-Asset | 0.77 | |||||
Debt-to-Equity | 0.14 | |||||
Debt-to-EBITDA | -26.31 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 3.03 | |||||
Beneish M-Score | -2.03 | |||||
WACC vs ROIC |
Growth Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 7 | |||||
3-Year EBITDA Growth Rate | 50.3 | |||||
3-Year EPS without NRI Growth Rate | 44.7 | |||||
3-Year Book Growth Rate | 9.1 | |||||
Future 3-5Y Total Revenue Growth Rate | -33.56 |
Momentum Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 77.69 | |||||
9-Day RSI | 84.07 | |||||
14-Day RSI | 85.22 | |||||
6-1 Month Momentum % | 0.92 | |||||
12-1 Month Momentum % | 6.11 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 9.51 | |||||
Quick Ratio | 9.51 | |||||
Cash Ratio | 9.25 | |||||
Days Sales Outstanding | 45.34 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5.6 | |||||
Shareholder Yield % | -28.4 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -4.63 | |||||
Net Margin % | 6.28 | |||||
FCF Margin % | -17.72 | |||||
ROE % | 3.5 | |||||
ROA % | 2.42 | |||||
ROIC % | -6.55 | |||||
ROC (Joel Greenblatt) % | -14.82 | |||||
ROCE % | -2.1 | |||||
Years of Profitability over Past 10-Year | 2 |
GF Value Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 36.41 | |||||
PE Ratio without NRI | 36.41 | |||||
PS Ratio | 2.92 | |||||
PB Ratio | 1.3 | |||||
Price-to-Tangible-Book | 1.3 | |||||
EV-to-EBIT | -16.52 | |||||
EV-to-EBITDA | -61.6 | |||||
EV-to-Forward-EBITDA | -1.08 | |||||
EV-to-Revenue | 0.77 | |||||
EV-to-Forward-Revenue | 1.5 | |||||
EV-to-FCF | -4.82 | |||||
Price-to-Projected-FCF | 4.35 | |||||
Price-to-Graham-Number | 1.45 | |||||
Price-to-Net-Current-Asset-Value | 1.56 | |||||
Price-to-Net-Cash | 1.61 | |||||
Earnings Yield (Greenblatt) % | -6.05 | |||||
FCF Yield % | -5.08 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Voyager Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil MXN) | 2,493.675 | ||
EPS (TTM) (MXN) | 3.619 | ||
Beta | 0.93 | ||
Volatility % | 28.25 | ||
14-Day RSI | 85.22 | ||
14-Day ATR (MXN) | 0.015672 | ||
20-Day SMA (MXN) | 165 | ||
12-1 Month Momentum % | 6.11 | ||
52-Week Range (MXN) | 130 - 167 | ||
Shares Outstanding (Mil) | 54.53 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Voyager Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Voyager Therapeutics Inc Stock Events
Event | Date | Price(MXN) | ||
---|---|---|---|---|
No Event Data |
Voyager Therapeutics Inc Frequently Asked Questions
What is Voyager Therapeutics Inc(MEX:VYGR)'s stock price today?
When is next earnings date of Voyager Therapeutics Inc(MEX:VYGR)?
Does Voyager Therapeutics Inc(MEX:VYGR) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |